Evaluation of clinical effects of a multidisciplinary-collaborated cancer support team for gastrointestinal cancer chemotherapy: prospective observational study protocol of M-CAST study.
Chemotherapy
Gastrointestinal cancer
Multidisciplinary-collaborated team
Supportive care
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
19 Jun 2023
19 Jun 2023
Historique:
received:
30
01
2023
accepted:
08
06
2023
medline:
21
6
2023
pubmed:
20
6
2023
entrez:
19
6
2023
Statut:
epublish
Résumé
Although the multidisciplinary-collaborated team approach in cancer treatment has recently become popular, prospectively evaluated evidence is limited. We started a multidisciplinary-collaborated cancer support team (MCST) to facilitate cooperation across multidisciplinary medical staff in our hospital and established clinical evidence of supportive care. This study aimed to prospectively evaluate the clinical activity and effect of MCST in patients with gastrointestinal cancer receiving chemotherapy. This is a single-center, single-arm, observational study. Patients with gastrointestinal cancer scheduled to receive chemotherapy are enrolled and supported by the MCST. The primary endpoints are the number of interventions by medical staff and the number of patients who showed improvement in side effects. The secondary endpoints are the severity of side effects, medical expenses, number of consultations, the acceptance rate of prescription recommendations, adjuvant chemotherapy completion rates, dose intensity, and time required for co-medical intervention. In addition, medical staff and attending physicians evaluate all adverse events. This study is expected to contribute to establishing new cancer-supportive care teams for patients with gastrointestinal cancer receiving chemotherapy and those with cancer receiving chemotherapy. This trial was registered in the Japan Registry of Clinical Trials (jRCT) as jRCT1030220495. The date of first registration, 29/11/2022, https://jrct.niph.go.jp/search.
Sections du résumé
BACKGROUND
BACKGROUND
Although the multidisciplinary-collaborated team approach in cancer treatment has recently become popular, prospectively evaluated evidence is limited. We started a multidisciplinary-collaborated cancer support team (MCST) to facilitate cooperation across multidisciplinary medical staff in our hospital and established clinical evidence of supportive care. This study aimed to prospectively evaluate the clinical activity and effect of MCST in patients with gastrointestinal cancer receiving chemotherapy.
METHODS
METHODS
This is a single-center, single-arm, observational study. Patients with gastrointestinal cancer scheduled to receive chemotherapy are enrolled and supported by the MCST. The primary endpoints are the number of interventions by medical staff and the number of patients who showed improvement in side effects. The secondary endpoints are the severity of side effects, medical expenses, number of consultations, the acceptance rate of prescription recommendations, adjuvant chemotherapy completion rates, dose intensity, and time required for co-medical intervention. In addition, medical staff and attending physicians evaluate all adverse events.
DISCUSSION
CONCLUSIONS
This study is expected to contribute to establishing new cancer-supportive care teams for patients with gastrointestinal cancer receiving chemotherapy and those with cancer receiving chemotherapy.
TRIAL REGISTRATION
BACKGROUND
This trial was registered in the Japan Registry of Clinical Trials (jRCT) as jRCT1030220495. The date of first registration, 29/11/2022, https://jrct.niph.go.jp/search.
Identifiants
pubmed: 37337152
doi: 10.1186/s12876-023-02849-6
pii: 10.1186/s12876-023-02849-6
pmc: PMC10280873
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
215Informations de copyright
© 2023. The Author(s).
Références
BMC Cancer. 2022 Nov 1;22(1):1119
pubmed: 36319973
J Oncol Pharm Pract. 2023 Jun;29(4):802-809
pubmed: 35164607
BMC Cancer. 2017 Feb 10;17(1):122
pubmed: 28187759
Biosci Trends. 2010 Aug;4(4):151-60
pubmed: 20811133
N Engl J Med. 2022 Feb 3;386(5):449-462
pubmed: 35108470
Contemp Oncol (Pozn). 2020;24(3):150-156
pubmed: 33235540
Nat Med. 2020 Dec;26(12):1859-1864
pubmed: 33020649
Oncology (Williston Park). 2008 Nov 15;22(12):1430-7
pubmed: 19086601
Eur J Hosp Pharm. 2018 Mar;25(e1):e17-e20
pubmed: 31157061
Crit Rev Oncol Hematol. 2015 Mar;93(3):203-10
pubmed: 25459671
JCO Oncol Pract. 2020 Apr;16(4):e350-e356
pubmed: 32048938
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
JCO Oncol Pract. 2020 Oct;16(10):e1209-e1215
pubmed: 32459565
Support Care Cancer. 2021 Nov;29(11):6505-6510
pubmed: 33905012
J Clin Oncol. 2021 Jun 20;39(18):1983-1994
pubmed: 33822650
J Clin Oncol. 2015 May 1;33(13):1453-9
pubmed: 25800766
Pan Afr Med J. 2011;9:20
pubmed: 22355430
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052
Lancet. 2021 Jul 3;398(10294):27-40
pubmed: 34102137